[New therapeutic concepts for vasculitis and collagenosis].
After improvement of the prognosis of the primary systemic vasculitides and systemic lupus erythematosus from a desperate diagnosis with hardly a one year survival after diagnosis to a 5-year-survival-rate of more than 90% actual therapeutic regimes aim at those patients refractory to standard therapeutic regimes, not achieving a remission by standard approaches or having organ damage or contraindications. Furthermore less toxic regimes are looked for with the aim to avoid secondary complications of the standard therapy. New drugs used successfully in rheumatology, transplantation medicine and haematology are used for these purposes in the last years. Recent experiences with Infliximab, Mycophenolate Mofetil, Rituximab und Deoxyspergualin for the treatment of the small vessel vasculitides and systemic lupus erythematosus are reviewed.
Metzler
C
C
Rheumaklinik Bad Bramstedt GmbH & Poliklinik für Rheumatologie, Universitätsklinikum Schleswig Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538 Lübeck.
Hellmich
B
B
Gause
A
A
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D003095:Collagen Diseases / Q000188:drug therapy*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D014657:Vasculitis / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents